Spectral AI Inc. is projected to post Q3 2026 revenue of $5.33 million and a consensus EPS loss of $0.14, with the current $1.56 share price trailing a bullish $5.11 average analyst price target. Investors are primarily focused on the commercialization progress of the DeepView AI System following its recent FDA De Novo clearance and the status of its New Technology Add-On Payment (NTAP) application.
Revenue for the period remains predominantly driven by the company's multi-year research and development contract with BARDA for burn diagnostic technology. Analysts will be closely monitoring management's guidance regarding the transition from R&D-based funding to commercial recurring revenue and updates on clinical trial expansions for diabetic foot ulcers.